UK industry welcomes Budget boosts for life sciences
New R&D tax incentive announced for SMEs in UK Budget | Funding for medicines regulator aims to open up drug approvals | ‘Hidden benefits’ in Budget for industry | Reaction from Bioindustry Association, Potter Clarkson, Mischon de Reya, Marks & Clerk, Taylor Wessing.
Novartis loses EU court bid to revoke inhaler trademark
Dispute relates to AstraZeneca ‘Breztri’ brand | Court says no likelihood of confusion with earlier marks | Full details of reasoning.
Edwards Lifesciences revives Fintiv challenge
Medtech company wins reversal of earlier ruling | Door opens to mount a challenge of controversial rule | USPTO director‘s updated guidelines influence court’s reasoning.
Abbott fails to stay claims in baby formula milk dispute
“Customer suit exception” is rejected by district judge | Suit between Chr. Hansen and Glycosyn is ongoing.
Don’t distort enablement law, Amgen tells SCOTUS
Sanofi and Regeneron accused of wanting to change patent system | The US Supreme Court will decide whether a controversial court decision should stand.
Gilead defeats immunity bid in hepatitis C patent case
The University of Minnesota had raised three key issues on appeal | Sovereign immunity was at the heart of the years-long dispute.
Genentech seeks ‘tens of millions in unpaid royalties’ in licence dispute
The Roche subsidiary says the licensee owes payments on “stockpile” of MS drug Tysabri.
WIPO: Pharma patents dwindle against record total growth
Health-related patents fell during 2022 against a backdrop of record global patents filed | Biotechnology was fastest growing field among Patent Cooperation Treaty applications | COVID-19 pandemic caused large falls in goods classes such as pharmaceuticals.
Vidal overturns PTAB decision on pig vaccine patent
Boehringer Ingelheim challenged university patent | Board must provide more details on ruling.
USPTO told to avoid negative focus on patent thickets
Pharma trade body highlighted negative narratives involving continuation patents | Such IP “essential for ongoing research and development” | USPTO requested comments following criticism of patent thickets.
